Prestige Collaborates with Dr. Reddy to Commercialize HD201, a Proposed Biosimilar to Herceptin for HER2 Positive Breast and Metastatic Gastric Cancer
Shots:
- Dr. Reddy gets exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia & will be responsible for local registrations, marketing, and sales in the licensed territories
- Prestige BioPharma will be responsible for the commercial supply of HD201 from its manufacturing facilities in Osong, South Korea
- Prestige BioPharma’s HD201 (trastuzumab) is a proposed biosimilar to Roche’s Herceptin and can be used for the treatment of HER2 positive breast and metastatic gastric cancer
Ref: Businesswire | Image: Prestige
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com